FLIXOTIDE 250 MCG EVOHALER
Pack Size: 1
Composition: Fluticasone Propionate (250ug)
Pharmaceutical form: Pressurized inhalation, suspension
Brand Name: [button link=”https://www.almishkat.pk/product-category/brand-companies/glaxo-smith-kline/” color=”purple” newwindow=”yes”] GlaxoSmithKline[/button]
Availability: In stock
- Reviews (0)
FLIXOTIDE 250 MCG EVOHALER
FLIXOTIDE 250 MCG EVOHALER does not contain any chlorofluorocarbons (CFCs). Fluticasone propionate given by inhalation offers prophylactic treatment for asthma. Adults: Mild asthma: Patients requiring intermittent symptomatic bronchodilator asthma medication on a regular daily basis
This medicine is used for treating seasonal or year around nasal allergic symptoms such as sneezing, runny/stuffy nose, and itching.
You may experience nasal irritation, taste disturbances, headache and anaphylaxis (life threatening allergic reaction).
When not to use
Do not use your FLIXOTIDE puffer if you have ever had an allergic reaction to fluticasone
Special warnings and precautions for use
The administration of asthma should follow a stepwise programme, and patient response ought to be monitored clinically and by lung function tests.
Patients’ inhaler technique ought to be assessed regularly to be certain inhaler actuation is synchronized with inspiration to ensure optimal delivery into the lungs. During childbirth, the individual should rather sit stand. The inhaler was made for use at a vertical posture.
Sudden and progressive deterioration in asthma control is potentially life threatening and attention needs to be given to increasing corticosteroid dose. Inpatients considered at risk, daily peak flow monitoring can be instituted.
Flixotide Evohaler isn’t meant to relieve serious symptoms in that an inhaled short-acting bronchodilator is required. Patients must be counseled to own such rescue drugs available.
Severe asthma requires regular medical examination, for example lung-function testing, even as patients are in danger of acute attacks and also death. Increasing utilization of short-acting inhaled β2-agonists to alleviate symptoms indicates deterioration of asthma management. If patients discover short-acting relief bronchodilator treatment becomes less effective, or else they want more inhalations than normal, medical attention must be hunted after. In this example patients needs to be re assessed and attention given to the demand for improved anti inflammatory therapy (e.g. higher dosages of inhaled corticosteroids or perhaps even a training program of oral corticosteroids). Acute exacerbations of asthma should be treated in the typical way.
There were very rare reports of gains in blood sugar levels, in patients without a brief history of diabetes mellitus (Watch 4.8’unwelcome Effects’). This is supposed to be viewed specifically when compared to patients having a history of diabetes mellitus.
Like other inhalation therapy, paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing. Flixotide Evohaler needs to be stopped immediately, the patient assessed and alternative therapy instituted if needed.